FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998331333> ?p ?o ?g. }

• W1998331333 endingPage "vi3" @default.
• W1998331333 startingPage "vi3" @default.
• W1998331333 abstract "ABSTRACT Background Complete responses with third-line or later salvage chemotherapy (CT) for GCT range from 5% to 10%, and nearly all patients (pts) progressing after high-dose CT will ultimately die. CD30 is expressed by embryonal carcinoma (ECA) thus lending support to a rationale for a targeted approach. SGN-35 is an antibody-drug conjugate consisting of the chimeric anti-CD30 antibody SGN-30 chemically conjugated to an antitubulin synthetic analog. The primary objective of the study will be the activity of SGN35 in refractory GCT. Trial design 24 pts with biopsy-proven CD30+ GCT will receive intravenous SGN35 at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity. Further eligibility requirements will include failure of 2 or 3 platinum-based CT (including HDCT). All pts will undergo measurement of serum tumor markers, a computed tomography and a PET scan q6 weeks. An optimal Simon's 2-stage design will be applied. The primary endpoint is the objective response-rate (ORR). An ORR of 5% is not promising, while a 25% rate will be promising. In stage 1, 9 evaluable patients will be accrued. If ≥1 patient will be responding, enrollment will be extended to the 2nd stage for further 15. If, over the total of 24 stage 1 plus stage 2 pts, 3 at least will be responding, treatment will be declared worthy for further investigations. The type I and II error are set both at 0.1 (power = 90%). We will test the hypothesis that brentuximab can promote anti-tumor immunity, which might contribute to the clinical efficacy. We will use multiparametric flow cytometry to assess whether SGN-35 can: a) impact on frequency and absolute counts of all main cellular subsets; b) shift the TH1/TH2 balance, in favor of a TH1-type of response; c) reduce the frequency of circulating CD30+ regulatory T cells and CD30+ TH2 memory T cells; d) promote an increase in circulating CD161+TH17 T cells; d) reverse the condition of immune dysfunction, by assessing the expression of negative co-signaling molecules (PD-1, CTLA-4, CD160, CD244, CD57, TIM-3, LAG-3) and of activation/proliferation markers (Ki67, GranzymeB, CD69) on main T cell subsets. As of July 2014, 6 pts have been enrolled (NCT01851200). Disclosure All authors have declared no conflicts of interest." @default.
• W1998331333 created "2016-06-24" @default.
• W1998331333 creator A5001956192 @default.
• W1998331333 creator A5055667895 @default.
• W1998331333 creator A5058849092 @default.
• W1998331333 creator A5061761089 @default.
• W1998331333 creator A5061875944 @default.
• W1998331333 creator A5067994961 @default.
• W1998331333 creator A5080811290 @default.
• W1998331333 creator A5083331837 @default.
• W1998331333 creator A5086507632 @default.
• W1998331333 creator A5090061046 @default.
• W1998331333 date "2014-11-01" @default.
• W1998331333 modified "2023-09-29" @default.
• W1998331333 title "Design of a Phase 2 STudy of Brentuximab Vedotin (SGN-35) as Salvage Therapy for Males with Chemoresistant Germ-Cell Tumors (GCT)" @default.
• W1998331333 doi "https://doi.org/10.1093/annonc/mdu467.14" @default.
• W1998331333 hasPublicationYear "2014" @default.
• W1998331333 type Work @default.
• W1998331333 sameAs 1998331333 @default.
• W1998331333 citedByCount "0" @default.
• W1998331333 crossrefType "journal-article" @default.
• W1998331333 hasAuthorship W1998331333A5001956192 @default.
• W1998331333 hasAuthorship W1998331333A5055667895 @default.
• W1998331333 hasAuthorship W1998331333A5058849092 @default.
• W1998331333 hasAuthorship W1998331333A5061761089 @default.
• W1998331333 hasAuthorship W1998331333A5061875944 @default.
• W1998331333 hasAuthorship W1998331333A5067994961 @default.
• W1998331333 hasAuthorship W1998331333A5080811290 @default.
• W1998331333 hasAuthorship W1998331333A5083331837 @default.
• W1998331333 hasAuthorship W1998331333A5086507632 @default.
• W1998331333 hasAuthorship W1998331333A5090061046 @default.
• W1998331333 hasBestOaLocation W19983313331 @default.
• W1998331333 hasConcept C126322002 @default.
• W1998331333 hasConcept C143998085 @default.
• W1998331333 hasConcept C2776694085 @default.
• W1998331333 hasConcept C2776938808 @default.
• W1998331333 hasConcept C2778191690 @default.
• W1998331333 hasConcept C2779338263 @default.
• W1998331333 hasConcept C2780775027 @default.
• W1998331333 hasConcept C31760486 @default.
• W1998331333 hasConcept C70905583 @default.
• W1998331333 hasConcept C71924100 @default.
• W1998331333 hasConceptScore W1998331333C126322002 @default.
• W1998331333 hasConceptScore W1998331333C143998085 @default.
• W1998331333 hasConceptScore W1998331333C2776694085 @default.
• W1998331333 hasConceptScore W1998331333C2776938808 @default.
• W1998331333 hasConceptScore W1998331333C2778191690 @default.
• W1998331333 hasConceptScore W1998331333C2779338263 @default.
• W1998331333 hasConceptScore W1998331333C2780775027 @default.
• W1998331333 hasConceptScore W1998331333C31760486 @default.
• W1998331333 hasConceptScore W1998331333C70905583 @default.
• W1998331333 hasConceptScore W1998331333C71924100 @default.
• W1998331333 hasLocation W19983313331 @default.
• W1998331333 hasOpenAccess W1998331333 @default.
• W1998331333 hasPrimaryLocation W19983313331 @default.
• W1998331333 hasRelatedWork W2003306594 @default.
• W1998331333 hasRelatedWork W2032082494 @default.
• W1998331333 hasRelatedWork W2105293222 @default.
• W1998331333 hasRelatedWork W2124197615 @default.
• W1998331333 hasRelatedWork W2389581939 @default.
• W1998331333 hasRelatedWork W2600735778 @default.
• W1998331333 hasRelatedWork W2803627681 @default.
• W1998331333 hasRelatedWork W2895753935 @default.
• W1998331333 hasRelatedWork W3160850296 @default.
• W1998331333 hasRelatedWork W4200134565 @default.
• W1998331333 hasVolume "25" @default.
• W1998331333 isParatext "false" @default.
• W1998331333 isRetracted "false" @default.
• W1998331333 magId "1998331333" @default.
• W1998331333 workType "article" @default.